European Sign Expo




Colour L*A*B* is an all-new feature arriving at FESPA Global Print Expo 2019, aimed at helping visitors improve colour management practices in their own print businesses.

The introduction of this feature for 2019 comes in response to feedback from FESPA’s stakeholders that they would like expert guidance on improving colour consistency and accuracy to meet ever-rising consumer expectations.

Colour L*A*B

What's on offer?

The feature provides a walk-through showcase of representative technologies from a range of specialist suppliers, live demonstrations, guided tours of the exhibit, and educational presentations from subject matter experts.

Visitors to Colour L*A*B* will be able to participate in free guided tours with respected colour management consultant Paul Sherfield, who will provide detailed explanations of the processes and answer visitors’ questions on how they can improve their own practices. Paul has also authored a series of colour management blog posts, which can be found on, to support the launch of this feature.

Additionally, the Colour L*A*B* conference area will offer a focused programme of free educational presentations from a range of subject matter experts, including Dr. Andreas Kraushaar of FOGRA and Paul Lindström of

Paul Sherfield, Colour Management Consultant

How do I find out more?

Further information regarding the individual technologies featured in Colour L*A*B* at FESPA Global Print Expo 2019, the detailed Colour L*A*B* conference programme and details on how to book sessions with the experts will be published in due course.

Attend Colour L*A*B* to get ahead of the game and find out how colour management can give you the edge.


European Sign Expo 2018 is conveniently co-located with FESPA Global Print Expo 2019 - Europe’s largest exhibition for screen and digital wide format print, fespa GPE Munich logotextile printing and signage. Over 4 days visitors will have the opportunity to experience the latest products and innovations on display from over 700 exhibitors.